image
Healthcare - Biotechnology - NASDAQ - US
$ 3.63
0.833 %
$ 622 M
Market Cap
-1.65
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RLAY stock under the worst case scenario is HIDDEN Compared to the current market price of 3.63 USD, Relay Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RLAY stock under the base case scenario is HIDDEN Compared to the current market price of 3.63 USD, Relay Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RLAY stock under the best case scenario is HIDDEN Compared to the current market price of 3.63 USD, Relay Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RLAY

image
$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
10 M REVENUE
-60.83%
-372 M OPERATING INCOME
0.14%
-338 M NET INCOME
1.25%
-249 M OPERATING CASH FLOW
17.05%
-41.1 M INVESTING CASH FLOW
-15.95%
270 M FINANCING CASH FLOW
677.35%
7.68 M REVENUE
0.00%
-84.9 M OPERATING INCOME
0.13%
-77.1 M NET INCOME
-1.40%
-73.2 M OPERATING CASH FLOW
-26.51%
42.5 M INVESTING CASH FLOW
46.44%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Relay Therapeutics, Inc.
image
Current Assets 809 M
Cash & Short-Term Investments 781 M
Receivables 0
Other Current Assets 27.9 M
Non-Current Assets 62.1 M
Long-Term Investments 0
PP&E 57.7 M
Other Non-Current Assets 4.42 M
89.67 %3.20 %6.62 %Total Assets$871.3m
Current Liabilities 50.7 M
Accounts Payable 14.1 M
Short-Term Debt 5.73 M
Other Current Liabilities 30.9 M
Non-Current Liabilities 42.8 M
Long-Term Debt 0
Other Non-Current Liabilities 42.8 M
15.08 %6.12 %33.05 %45.75 %Total Liabilities$93.5m
EFFICIENCY
Earnings Waterfall Relay Therapeutics, Inc.
image
Revenue 10 M
Cost Of Revenue 5.46 M
Gross Profit 4.54 M
Operating Expenses 382 M
Operating Income -372 M
Other Expenses -34.8 M
Net Income -338 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)10m(5m)5m(382m)(372m)35m(338m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
45.40% GROSS MARGIN
45.40%
-3722.07% OPERATING MARGIN
-3722.07%
-3374.72% NET MARGIN
-3374.72%
-43.42% ROE
-43.42%
-38.76% ROA
-38.76%
-45.08% ROIC
-45.08%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Relay Therapeutics, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)20192019202020202021202120222022202320232024202420252025
Net Income -338 M
Depreciation & Amortization -6.85 M
Capital Expenditures -2.02 M
Stock-Based Compensation 94.1 M
Change in Working Capital 0
Others 5.66 M
Free Cash Flow -251 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Relay Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for RLAY of $18 , with forecasts ranging from a low of $16 to a high of $20 .
RLAY Lowest Price Target Wall Street Target
16 USD 340.77%
RLAY Average Price Target Wall Street Target
18 USD 395.87%
RLAY Highest Price Target Wall Street Target
20 USD 450.96%
Price
Max Price Target
Min Price Target
Average Price Target
20201818161614141212101088664422Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Relay Therapeutics, Inc.
image
Sold
0-3 MONTHS
417 K USD 5
3-6 MONTHS
3.89 M USD 5
6-9 MONTHS
752 K USD 5
9-12 MONTHS
1.33 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. globenewswire.com - 3 weeks ago
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer globenewswire.com - 1 month ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats in June: Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:45 a.m. globenewswire.com - 1 month ago
What Makes Relay Therapeutics (RLAY) a New Buy Stock Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 1 month ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: globenewswire.com - 1 month ago
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations Approximately $710 million in cash, cash equivalents and investments at end of Q1 2025 CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2025 financial results and corporate updates. globenewswire.com - 2 months ago
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025 CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Monday, May 5, 2025. globenewswire.com - 2 months ago
Top Cancer Stocks to Buy to Boost Your Portfolio's Health If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics. zacks.com - 2 months ago
Relay Therapeutics: Trying To Find That Right Price Relay Therapeutics' pipeline has shifted, with the FGFR2 inhibitor lirafugratinib outlicensed to Elevar, bringing in cash and royalties, but losing global rights. RLY-2608, a PI3K-alpha inhibitor, shows promise in breast cancer trials, with plans for a phase 3 trial and potential in other cancers. Financially, RLAY holds $124.3M in cash and $657M in investments, with a cash runway into mid-2026, bolstered by recent cost-saving measures. seekingalpha.com - 2 months ago
Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY) The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com - 4 months ago
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer globenewswire.com - 4 months ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 1:50 p.m. globenewswire.com - 4 months ago
8. Profile Summary

Relay Therapeutics, Inc. RLAY

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 622 M
Dividend Yield 0.00%
Description Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Contact 399 Binney Street, Cambridge, MA, 02139 https://www.relaytx.com
IPO Date July 16, 2020
Employees 259
Officers Mr. Matthew P. Jacobson Ph.D. Founder Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS Chief Executive Officer, President & Director Dr. Beni B. Wolf M.D., Ph.D. Chief Medical Officer & Head of Precision Medicine Dr. Donald A. Bergstrom M.D., Ph.D. President of Research & Development Mr. Peter Rahmer Chief Corporate Development Officer Ms. Dorothee Kern Ph.D. Founder Mr. Jim Watters Ph.D. Chief Scientific Officer Dr. David Elliot Shaw Ph.D. Founder Mr. Thomas Catinazzo Chief Financial Officer Mr. Brian R. Adams J.D. Chief Legal Officer & Secretary